RUZURGI^® (amifampridine)
10 mg Tablets

NOW AVAILABLE TO PRESCRIBE AND COVERED BY MANY PROVINCES

Medunik Canada is pleased to announce that Ruzurgi^® (amifampridine 10 mg tablets) is now available to prescribe and is covered by the Alberta drug benefit plan Alberta (AHS), First Nations (NIHB – Non insured health benefits) and the régie de l'assurance maladie du québec (RAMQ), The British Columbia PharmaCare and Veterans Affairs Canada.

This recent product availability and coverage will allow your Lambert-Eaton Myasthenic Syndrome (LEMS) patients easier access to Ruzurgi^®.  Make sure to review the proper criteria to ensure timely and seamless coverage.

Medunik has had significant success in a short period of time in making Ruzurgi^® accessible in several provinces. We are also making progress in other jurisdictions to hopefully gain national public coverage soon. Most private insurance companies already cover Ruzurgi^®. Coverage may vary depending on the plans specific criteria.

We understand how difficult it can be for patients with rare and debilitating diseases such as LEMS to get access to treatments and we remain committed to working with our health authorities across Canada to ensure patients have optimal coverage both from a private and public insurance perspective. We are also working hard towards putting together a Patient Support Program (PSP) to better support Healthcare Professionals and their patients.  We will make an announcement as soon as it is available.

Medunik Canada is a Canadian owned and operated company, based in Blainville dedicated to improving the health and quality of life of Canadians with rare diseases.

For any questions, please click here to contact our Medical information Department.